Pemetrexed Solution, Concentrate
Product Images NDC 0480-4515

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Pemetrexed (NDC 0480-4515). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Teva Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (Image 1)

Chemical structure of the active ingredient pemetrexed, including its characteristic bicyclic and aromatic rings with attached carboxyl and amine functional groups, and a water molecule (hydrate) indicated.*

FDA Label Image

1 (Image 2)

A Kaplan-Meier survival curve graph showing survival probability over time in months for two groups: Pemetrexed and Placebo. The x-axis represents survival time in months, and the y-axis represents survival probability from 0 to 1. The graph compares patient survival between Pemetrexed (solid line) and Placebo (dotted line). A table below lists patients at risk at various time points for each group.*

FDA Label Image

1 (Image 3)

A survival probability curve comparing Pemetrexed and placebo treatments over a 42-month period. The y-axis represents survival probability from 0.0 to 1.0, and the x-axis shows survival time in months. The solid line for Pemetrexed displays higher survival rates than the dotted placebo line. Below the graph, the number of patients at risk at various time points is listed for both groups.*

FDA Label Image

1 (Image 4)

A Kaplan-Meier survival curve chart comparing survival probability over time (months) between patients treated with Pemetrexed and a placebo. The chart includes survival curves with Pemetrexed shown as a solid line and placebo as a dotted line, and a table of patients at risk over time for both groups.*

FDA Label Image

1 (Image 5)

A Kaplan-Meier survival curve comparing survival probability over time (months) between patients treated with Pemetrexed and those given a placebo. The graph includes a legend, with a solid line for Pemetrexed and a dotted line for placebo, and a table below showing the number of patients at risk at various time points for each group.*

FDA Label Image

1 (Image 6)

The packaging label for Pemetrexed Injection, 100 mg/4 mL (25 mg/mL) solution concentrate for intravenous use, manufactured by Teva Pharmaceuticals, Inc. This 4 mL single-dose vial label includes directions to dilute before intravenous infusion, warnings for cytotoxicity, storage instructions, and dilution details. The label features barcodes, lot information, and manufacturer addresses.*

FDA Label Image

1 (Image 7)

Packaging label for Pemetrexed Injection 500 mg/20 mL (25 mg/mL) solution concentrate for intravenous use by Teva Pharmaceuticals, Inc. The label states it is a 20 mL single-dose vial with instructions for dilution, storage (refrigerate), and warnings including cytotoxic agent caution and to discard unused portions. The label includes NDC 0480-4514-01 and manufacturer information in Romania.*

FDA Label Image

1 (Image 8)

Packaging label for Pemetrexed Injection 1 g/40 mL (25 mg/mL) solution concentrate for intravenous use. The label indicates it is a cytotoxic agent, must be diluted before infusion, stored refrigerated, and is for single-dose 40 mL vials. Manufactured for Teva Pharmaceuticals, Inc. The label includes dosage, storage instructions, and warnings.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.